PPMI Biofluid Biomarkers Program RFA Grant

PPMI Biofluid Biomarkers Program RFA Grant

Status: ACTIVE
Funder: Michael J Fox Foundation For Parkinsons Research
Amount: Up to US $750,000
Last Updated: May 13, 2025

Summary

The PPMI Biofluid Biomarkers Program RFA invites collaborators to enhance Parkinson's disease (PD) research through validated biomarker assays. Projects should focus on identifying alpha-synuclein pathology, understanding PD initiation and progression biologically, characterizing known dementia biomarkers, and correlating clinical progression. Funding of up to $750,000 is available, reflecting the scope of work proposed. This initiative aims to improve the biological understanding of PD and related disorders.

Overview

PPMI Biofluid Biomarkers Program RFA This Parkinson’s Progression Markers Initiative (PPMI) program seeks to identify collaborators who have analytically validated biomarker assays to deploy in existing PPMI biosamples to enhance the biological definition of Parkinson’s disease (PD) and related disorders, both before and after symptom onset. Projects must address the following strategic goals: Identify biomarkers of alpha-synuclein pathology beyond the alpha-synuclein seed amplification assay. Understand biologic endotypes of initiation/progression of PD using targeted/unbiased omics. Comprehensively characterize known biomarkers of dementia, neurodegeneration and copathology. Advance characterization across the progression of PD to predict and correlate with progression on motor, cognitive and other clinical domains. Funding Up to $750,000. Requested support should be commensurate with work proposed.

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.